沙利度胺联合吉西他滨及奥沙利铂方案治疗中晚期肝癌的临床对照研究

目的观察沙利度胺联合吉西他滨及奥沙利铂组成的Gemox方案治疗中晚期肝癌前后VEGF的变化及不良反应。方法56例中晚期肝癌患者,随机分为两组,治疗组29例采用沙利度胺联合吉西他滨及奥沙利铂组成的Gemox方案治疗,对照组27例采用吉西他滨联合奥沙利铂的Gemox方案治疗。治疗2个周期后观察临床疗效,并检测治疗前后VEGF水平的变化。结果两组有效率分别为51.72%和44.44%,差异无统计学意义(P>0.05)。治疗组治疗后VEGF较治疗前明显下降,对照组治疗前后VEGF变化的水平不明显(P>0.05)。两组不良反应的发生无明显差异,治疗组KPS评分明显高于对照组。结论沙利度胺联合Gemox方案有望提高中晚期肝癌的治疗有效率,降低血清VEGF,且能改善患者的一般状况,提高患者对全身化疗的耐受性。

The clinical control study of thalidomide combined with Gemox regimen for advanced hepatocellular cancer

Objective To explore the therapeutic effect and changes of VEGF of thalidomide combined with Gemox regimen for adcanced hepatocellular cancer.Methods Fifty-six hepatocellular cancer patients were divided randomly into two groups.The trial group(29 cases) were treated with thalidomide and Gemox regimen while the control group(27 cases) were treated with Gemox regimen only.The clinical effect and VEGF level were observed after two cycles treatment.Results There was no obvious difference in the effective rate between two groups,which were 51.72% and 44.44% seperately.However,the level of VEGF in the trial group after two cycles treatment was lower than before treatment.There was no obvious difference in the level of VEGF before and after treatment in control group.There was no obvious difference in side effect between two groups.Conclusion Combination of thalidomide and Gemox regimen could decrease the level of VEGF,and also improve the survival quality of patients.